NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Accelmed Partners Ii L.P. Acquires 327,893 Shares of Stock

NeuroPace, Inc. (NASDAQ:NPCEGet Rating) major shareholder Accelmed Partners Ii L.P. acquired 327,893 shares of NeuroPace stock in a transaction that occurred on Monday, November 21st. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $491,839.50. Following the completion of the purchase, the insider now directly owns 4,370,550 shares of the company’s stock, valued at $6,555,825. The acquisition was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

NeuroPace Price Performance

Shares of NPCE traded up $0.05 during trading hours on Thursday, reaching $1.55. The stock had a trading volume of 7,211 shares, compared to its average volume of 154,600. The company has a debt-to-equity ratio of 1.20, a quick ratio of 10.17 and a current ratio of 11.08. NeuroPace, Inc. has a 12 month low of $1.38 and a 12 month high of $12.52. The stock has a market capitalization of $38.60 million, a PE ratio of -0.81 and a beta of 1.10. The company’s 50-day moving average is $2.85 and its two-hundred day moving average is $4.49.

NeuroPace (NASDAQ:NPCEGet Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. NeuroPace had a negative return on equity of 80.18% and a negative net margin of 106.63%. The business had revenue of $11.16 million during the quarter, compared to analysts’ expectations of $10.32 million. Research analysts expect that NeuroPace, Inc. will post -1.97 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley reduced their price target on shares of NeuroPace from $5.50 to $3.50 and set an “underweight” rating on the stock in a research note on Tuesday, October 11th.

Institutional Investors Weigh In On NeuroPace

Several hedge funds have recently added to or reduced their stakes in the business. Financial Advocates Investment Management acquired a new position in NeuroPace in the 3rd quarter valued at approximately $38,000. Renaissance Technologies LLC bought a new stake in NeuroPace in the second quarter valued at approximately $63,000. Citadel Advisors LLC acquired a new stake in shares of NeuroPace during the second quarter worth $108,000. Opaleye Management Inc. bought a new position in NeuroPace during the second quarter worth $446,000. Finally, State Street Corp lifted its holdings in NeuroPace by 2.1% in the first quarter. State Street Corp now owns 98,717 shares of the company’s stock valued at $810,000 after buying an additional 2,042 shares during the period. 74.19% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

(Get Rating)

NeuroPace, Inc operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely.

See Also

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.